Skip to main
  1. Stocks
  2. Myriad Genetics
  3. Forecast
MYGN

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 7 analyst ratings
Hold
Strong Buy 14%
Buy 0%
Hold 71%
Sell 14%
Strong Sell 0%

Bulls say

Myriad Genetics is viewed positively because 3Q26 showed a clear operating beat, with total revenue of $202.7M, gross margin of 68.2%, and adjusted EBITDA of -$5.3M all outperforming expectations, while volume growth and improved ASP trends across CCC, HCT, and Mental Health signal healthier underlying demand. The company also raised FY26 revenue guidance to $780M-$790M and has $107.1M in cash plus about $182M of available capital, giving it flexibility to support growth and execution. Longer term, the planned Prenatal divestiture for $210M is expected to lift growth by more than 100 bps and gross margin by more than 500 bps, while ASCEND and reimbursement initiatives should improve profitability and cash generation.

Bears say

Myriad Genetics is facing a weak fundamental setup because competition is intense across prenatal, oncology, and mental health testing, while pricing pressure in mature hereditary cancer markets continues to erode average selling prices and limits organic growth. The company’s recent results underscore structural issues: revenue declined low double digits, margins compressed 460 bps year over year, prenatal revenue fell 16% to about $40 million, and guidance was cut by $90 million at the midpoint, suggesting demand and reimbursement challenges are not temporary. Although the Prenatal sale improves cash runway and may help margins, the business still lacks clear evidence that new products can offset share loss, stabilize pricing, and restore sustainable profitability.

Myriad Genetics (MYGN) has been analyzed by 7 analysts, with a consensus rating of Hold. 14% of analysts recommend a Strong Buy, 0% recommend Buy, 71% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Myriad Genetics (MYGN) Analyst Forecast & Price Prediction

Get the latest Myriad Genetics (MYGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Myriad Genetics (MYGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 7 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Nov 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.34, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.34, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Myriad Genetics (MYGN) Analyst Forecast & Price Prediction

Get the latest Myriad Genetics (MYGN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Myriad Genetics (MYGN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MYGN stock data and trends